background: the biolimus-eluting stent (bes), with a biodegradable polymer, has not been previously compared with the everolimus-eluting stent (ees), as a second-generation drug-eluting stent (des).we sought to compare the 1-year outcome between the promus ™ stent (ees type) and the biomatrix ™ stent (bes type). methods: from march 2008 to september 2011, all patients treated with the promus™ s...

OBJECTIVE To compare the efficacy and safety of biodegradable polymer drug eluting stents with those of bare metal stents and durable polymer drug eluting stents. DESIGN Mixed treatment comparison meta-analysis of 258,544 patient years of follow-up from randomized trials. DATA SOURCES AND STUDY SELECTION PubMed, Embase, and Central were searched for randomized trials comparing any of the Fo...

OBJECTIVES To explore the 2-year clinical outcomes in patients with unprotected left main coronary artery (ULMCA) disease treated with overall new drug-eluting stent (DES) options. BACKGROUND Recent available data have shown the feasibility and the safety of new DESs, mainly evaluating the everolimus-eluting stents in the setting of ULMCA disease. METHODS Patients with ULMCA disease undergo...

OBJECTIVES The aim of this study was to compare the pharmacokinetics of the four limus-eluting stents used in Japanese patients. BACKGROUND There are presently no reports comparing human pharmacokinetics among drug-eluting stents (DESs). METHODS We retrospectively analyzed data from pharmacokinetic studies of patients implanted with an 18-mm DES: Cypher stent (sirolimus, n = 10), Endeavor s...

OBJECTIVES To evaluate the efficacy and safety of currently used drug eluting stents compared with each other and compared with bare metal stents in patients with diabetes. DESIGN Mixed treatment comparison meta-analysis. DATA SOURCES AND STUDY SELECTION PubMed, Embase, and CENTRAL were searched for randomised clinical trials, until April 2012, of four durable polymer drug eluting stents (s...

Objective To compare the efficacy and safety of biodegradable polymer drug eluting stents with those of bare metal stents and durable polymer drug eluting stents. Design Mixed treatment comparison meta-analysis of 258 544 patient years of follow-up from randomized trials. Data sources and study selection PubMed, Embase, and Central were searched for randomized trials comparing any of the Food a...

BACKGROUND Recent data have suggested that patients with coronary disease in large arteries are at increased risk for late cardiac events after percutaneous intervention with first-generation drug-eluting stents, as compared with bare-metal stents. We sought to confirm this observation and to assess whether this increase in risk was also seen with second-generation drug-eluting stents. METHOD...

INTRODUCTION AND OBJECTIVES To compare the 3-year incidence of major events in patients with bifurcation lesions treated with provisional sirolimus-eluting stents vs everolimus-eluting stents. METHODS A pooled analysis of 2 prospective randomized trials with similar methodology (SEAside and CORpal) was performed. In these trials, 443 patients with bifurcation lesions were randomly assigned to...

Background—Drug-eluting stents significantly improved angiographic and clinical outcomes compared with bare metal stents in diabetic patients. However, a comparison of everolimus-eluting stents and sirolimus-eluting stents in diabetic patients has not been evaluated. Therefore we compared effectiveness of everolimus-eluting stents and sirolimus-eluting stents in patients with diabetes mellitus....

Bare metal stents have a proven safety record, but limited long-term efficacy due to in-stent restenosis. First-generation drug-eluting stents successfully countered the restenosis rate, but were hampered by concerns about their long-term safety. Second generation drug-eluting stents have combined the low restenosis rate of the first generation with improved long-term safety. We review the evol...